Mindevi Deuremidevir Hydrobromide Tablets

1. Indications and Usage
COVID-19: Indicated for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult patients. It should be administered as soon as possible after symptoms appear, ideally within 3 days of symptom onset.
2. Dosage and Administration
Route of Administration: Oral administration. Can be taken with or without food.
Recommended Dosage: The treatment duration is 5 days. On Day 1 (the first 2 doses), the dosage is 0.6g every 12 hours. On Days 2-5 (the remaining 8 doses), the dosage is 0.3g every 12 hours.
3. Mechanism of Action
RdRp Inhibition: Deuremidevir is a nucleoside prodrug that is metabolized intracellularly into its active triphosphate form.
Replication Blockade: It directly targets and inhibits the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, thereby blocking viral RNA replication and exerting antiviral effects.
4. Safety and Warnings
Contraindications: Hypersensitivity to deuremidevir hydrobromide or any excipients. It is contraindicated during pregnancy.
Hepatic Impairment: No clinical studies have been conducted in patients with hepatic impairment. Clinical trial data showed a similar rate of liver function abnormalities compared to placebo; monitoring is advised.
Lactation: Breastfeeding is not recommended during treatment and for 7 days after the last dose.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: The most frequently reported adverse reactions include liver function abnormalities, hyperlipidemia, hyperuricemia, hypoproteinemia, and increased blood pressure.
Clinical Research Highlights: Clinical trials demonstrated that deuremidevir significantly shortened the time to resolution of persistent clinical symptoms compared to placebo, with a safety profile comparable to the placebo group.
6. Drug Interactions
Transporters: In vitro studies indicate that the main metabolite of deuremidevir does not inhibit P-gp, BCRP, OAT3, or OCT2, but may inhibit MATE1, MATE2-K, OAT1, and OATP1B.
General Caution: No formal drug-drug interaction studies have been conducted; caution is advised when co-administering other medications.
7. Pharmaceutical Information
Chemical Composition: Active ingredient: Deuremidevir hydrobromide.
Appearance: Tablets (commonly 0.1g per tablet).
Packaging: Available in various packaging sizes.
Storage: Store at controlled room temperature; protect from moisture and light.